Identification of target genes using gene expression profile of granulocytes from patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

References

• Luatti S, et al. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood 2012;120:761–767.
   PubMed Web of Science ®Google Scholar
• Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343–3356.
   PubMed Web of Science ®Google Scholar
• Baran Y, Saydam G. Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia. J Blood Med 2012;3:139–150.
   PubMedGoogle Scholar
• Melo JV, Hughes TP, Apperley JF. Chronic myeloid leukemia. Hematology Am Soc Hematol Educ Program 2003:132–152.
   PubMedGoogle Scholar
• Mascarenhas CC, et al. New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma 2009;50:1148–1154.
   PubMed Web of Science ®Google Scholar
• Wong S, et al. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations. Proc Natl Acad Sci USA 2004;101:17456–17461.
   PubMed Web of Science ®Google Scholar
• Inokuchi K. Chronic myelogenous leukemia: from molecular biology to clinical aspects and novel targeted therapies. J Nippon Med Sch 2006;73:178–192.
   PubMedGoogle Scholar
• Park S, et al. Application of array comparative genomic hybridization in chronic myeloid leukemia. Methods Mol Biol 2013;973:55–68.
   PubMedGoogle Scholar
• Remsing Rix LL, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009;23:477–485.
   PubMed Web of Science ®Google Scholar
• Canalli AA, et al. Granulocytic adhesive interactions and their role in sickle cell vaso-occlusion. Hematology 2005;10:419–425.
   PubMed Web of Science ®Google Scholar
• Diatchenko L, et al. Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific cDNA probes and libraries. Proc Natl Acad Sci USA 1996;93:6025–6030.
   PubMed Web of Science ®Google Scholar
• Diatchenko L, et al. Suppression subtractive hybridization: a versatile method for identifying differentially expressed genes. Methods Enzymol 1999;303:349–380.
   PubMed Web of Science ®Google Scholar
• Hillmann A, Dunne E, Kenny D. cDNA amplification by SMART-PCR and suppression subtractive hybridization (SSH)-PCR. Methods Mol Biol 2009;496:223–243.
   PubMedGoogle Scholar
• Ewing B, et al. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res 1998;8:175–185.
   PubMed Web of Science ®Google Scholar
• Ghosh S, et al. Global gene expression and Ingenuity biological functions analysis on PCBs 153 and 138 induced human PBMC in vitro reveals differential mode(s) of action in developing toxicities. Environ Int 2011;37:838–857.
   PubMed Web of Science ®Google Scholar
• Gilmore TD. The Rel/NF-kappaB signal transduction pathway: introduction. Oncogene 1999;18:6842–6844.
   PubMed Web of Science ®Google Scholar
• Samy RP, et al. Identification of a novel Calotropis procera protein that can suppress tumor growth in breast cancer through the suppression of NF-kappaB pathway. PLoS One 2012;7:e48514.
   PubMed Web of Science ®Google Scholar
• Albensi BC, Mattson MP. Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. Synapse 2000;35:151–159.
   PubMed Web of Science ®Google Scholar
• Li F, Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 2010;1805:167–180.
   PubMed Web of Science ®Google Scholar
• Pezzolesi MG, et al. Comparative genomic and functional analyses reveal a novel cis-acting PTEN regulatory element as a highly conserved functional E-box motif deleted in Cowden syndrome. Hum Mol Genet 2007;16:1058–1071.
   PubMed Web of Science ®Google Scholar
• Bidere N, et al. Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival. Nature 2009;458:92–96.
   PubMed Web of Science ®Google Scholar
• Cerveira N, Bizarro S, Teixeira MR. MLL-SEPTIN gene fusions in hematological malignancies. Biol Chem 2011;392:713–724.
   PubMed Web of Science ®Google Scholar
• Zhao LJ, et al. Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia. Blood 2012;119:2873–2882.
   PubMed Web of Science ®Google Scholar
• Ichikawa M, et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 2004; 10:299–304.
   PubMed Web of Science ®Google Scholar
• Blackmore TM, et al. The transcriptional cofactor MIER1-beta negatively regulates histone acetyltransferase activity of the CREB-binding protein. BMC Res Notes 2008;1:68.
   PubMedGoogle Scholar
• Kohler M, et al. Evidence for distinct substrate specificities of importin alpha family members in nuclear protein import. Mol Cell Biol 1999;19:7782–7791.
   PubMed Web of Science ®Google Scholar
• Murati A, et al. Myeloid malignancies: mutations, models and management. BMC Cancer 2012;12:304.
   PubMed Web of Science ®Google Scholar
• Daver N, et al. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol 2013;88:56–59.
   PubMed Web of Science ®Google Scholar
• Bai Y, et al. Itch E3 ligase-mediated regulation of TGF-beta signaling by modulating smad2 phosphorylation. Mol Cell 2004;15: 825–831.
   PubMed Web of Science ®Google Scholar
• Tzachanis D, et al. Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat Immunol 2001;2: 1174–1182.
   PubMed Web of Science ®Google Scholar
• Naka K, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010;463: 676–680.
   PubMed Web of Science ®Google Scholar
• Ezzeddine N, et al. Human TOB, an antiproliferative transcription factor, is a poly(A)-binding protein-dependent positive regulator of cytoplasmic mRNA deadenylation. Mol Cell Biol 2007;27:7791–7801.
   PubMed Web of Science ®Google Scholar
• Kundu J, et al. Tob1 induces apoptosis and inhibits proliferation, migration and invasion of gastric cancer cells by activating Smad4 and inhibiting betacatenin signaling. Int J Oncol 2012;41:839–848.
   PubMed Web of Science ®Google Scholar